OncoMatch/Clinical Trials/NCT06961955
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Is NCT06961955 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 estrogen receptor positivity less than 5%
Estrogen receptor positivity less than 5%
Disease stage
Excluded: Stage NODE POSITIVE, METASTASES
Breast cancer stage (AJCC v8) T0-3, N0, M0. T0 N0 is allowed if whole breast radiation is recommended by the treating physician.
Performance status
ECOG OR KPS 0–2
ECOG Performance Status ≤ 2, or KPS ≥ 50
Prior therapy
Must have received: lumpectomy
Lumpectomy within 84 days of the start of radiation.
Cannot have received: radiation therapy to the chest
Prior radiation therapy to the chest.
Cannot have received: chemotherapy
Prior chemotherapy.
Cannot have received: prior breast malignancy
Prior breast malignancy in either breast.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify